Report Detail Page
Annual ryegrass toxicity vaccine commercialisation plan - WP383
Efforts to attract a commercial partner to develop the Annual Rye Grass Toxicity (ARGT) vaccine have not been successful. The key obstacle is the limited size of the market. The disease is primarily confined to sheep in WA while the technology appears to have no wider application.
|Contract No.||Title||Start date||End date||Funding type|
Annual Ryegrass Toxicity Vaccine Commercialistation Plan - WP383
This page was last updated on 06/07/2018
Join myMLA today
One username and password for key integrity and information Systems (LPA/NVD, NLIS, MSA & LDL).
A personalised online dashboard that provides news, weather, events and R&D tools relevant to you.
Customised market information and analysis.
Already registered for myMLA?